TNFSF10 and hydrops fetalis: In light of these experimental data, the aim of the present study was to measure the serum levels of TRAIL in a cohort of AMI patients, both at baseline (within 24 hours from AMI) and in the follow-up (up to 12 months from AMI), and to assess the relationship between TRAIL and short- and long-term incidence of cardiovascular death and/or heart failure (HF).